Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
4.773
Zitationen
19
Autoren
2007
Jahr
Abstract
As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects. (ClinicalTrials.gov number, NCT00073307 [ClinicalTrials.gov].).
Ähnliche Arbeiten
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 · 15.283 Zit.
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
2013 · 6.569 Zit.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
2015 · 5.846 Zit.
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 · 5.733 Zit.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
2018 · 4.547 Zit.
Autoren
Institutionen
- Institut Gustave Roussy(FR)
- Cancer Research UK Cambridge Center(GB)
- University of Chicago(US)
- Hôpital Européen Georges-Pompidou(FR)
- Hôpital Européen(FR)
- Ludwig-Maximilians-Universität München(DE)
- Centre Léon Bérard(FR)
- Institut Claudius Regaud(FR)
- Institut Génétique Nantes Atlantique(FR)
- Centrum Onkologii(PL)
- Royal Marsden Hospital(GB)
- Bayer (United States)(US)
- Cleveland Clinic(US)